Ixazomib citrate is used as an oral proteasome inhibitor in the treatment of multiple myeloma. It is typically administered in combination with other agents such as lenalidomide and dexamethasone for patients who have received at least one prior therapy. Its oral formulation offers a convenient alternative to intravenous treatments, improving patient compliance and enabling outpatient management. The drug works by disrupting protein degradation in cancer cells, leading to cell cycle arrest and apoptosis. It is also being studied in various hematologic malignancies and treatment regimens to expand its clinical utility.